Literature DB >> 8748278

Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay.

J M Pawlotsky1, A Bastie, C Pellet, J Remire, F Darthuy, L Wolfe, C Sayada, J Duval, D Dhumeaux.   

Abstract

Indeterminate hepatitis C virus (HCV) third-generation recombinant immunoblot assay (RIBA3.0; Ortho Diagnostic Systems) patterns were arbitrarily defined by the manufacturer as the detection of only one antibody out of the four that were sought, namely, c100 (NS4 encoded), c22 (core encoded), c33c (NS3 encoded), and NS5 (NS5 encoded). The aims of the present study were (i) to determine the prevalence of indeterminate RIBA3.0 patterns in patients consecutively tested for anti-HCV antibodies in a university hospital; (ii) to evaluate the significance of these patterns in terms of viral replication, liver disease, and risk factors for HCV; and (iii) to get an insight into the mechanism underlying this peculiar immune response. Among 3,074 serum samples consecutively tested for anti-HCV antibodies, 588 were found to be positive by screening assays. Fifty-nine of them (10%) were RIBA3.0 indeterminate and were compared with 59 RIBA3.0-positive ones. Thirty-one RIBA3.0-indeterminate and 53 RIBA3.0-positive serum samples were HCV RNA positive by PCR (53 versus 90%; P < 10(-6). RIBA3.0-indeterminate and RIBA-3.0-positive patients with positive PCR results were not significantly different for the prevalence of risk factors for HCV infection and elevated serum alanine aminotransferase activities. Immunosuppression, attributable to coexisting human immunodeficiency virus infection, organ transplantation, or the administration of immunosuppressive drugs, was significantly more frequent in PCR-positive, RIBA3.0-indeterminate patients than in PCR-negative, RIBA3.0 indeterminate patients (P < 0.001) and PCR-positive patients with a positive RIBA3.0 result (P < 0.01). The distribution of HCV genotypes did not differ significantly between HCV RNA-positive patients with indeterminate or positive RIBA3.0 results. In conclusion, the prevalence of indeterminate RIBA3.0 patterns in virology laboratories is about 10%; in about half of these patients HCV replication is detected by PCR; the main factor responsible for indeterminate RIBA3.0 patterns could be immunosuppression, whereas HCV genotypes do not seem to play major role.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8748278      PMCID: PMC228735          DOI: 10.1128/jcm.34.1.80-83.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  HCV confirmatory testing of blood donors.

Authors:  E A Follett; B C Dow; F McOmish; P L Yap; W Hughes; R Mitchell; P Simmonds
Journal:  Lancet       Date:  1991-10-19       Impact factor: 79.321

2.  Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients.

Authors:  A S Lok; D Chien; Q L Choo; T M Chan; E K Chiu; I K Cheng; M Houghton; G Kuo
Journal:  Hepatology       Date:  1993-09       Impact factor: 17.425

3.  Indeterminate hepatitis C.

Authors:  X M Li; K R Reddy; L J Jeffers; T Parker; M de Medina; E R Schiff
Journal:  Lancet       Date:  1993-03-27       Impact factor: 79.321

4.  A prospective study of hepatitis C virus infection among renal transplant recipients.

Authors:  T M Chan; A S Lok; I K Cheng; R T Chan
Journal:  Gastroenterology       Date:  1993-03       Impact factor: 22.682

5.  The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV "seroreversion".

Authors:  M V Ragni; O K Ndimbie; E O Rice; F A Bontempo; S Nedjar
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

6.  Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients.

Authors:  D Bresters; H L Zaaijer; H T Cuypers; H W Reesink; I N Winkel; P J van Exel-Oehlers; A A van Drimmelen; P L Jansen; C L van der Poel; P N Lelie
Journal:  Transfusion       Date:  1993-08       Impact factor: 3.157

7.  Hepatitis C virus infection in kidney transplant recipients.

Authors:  J Y Lau; G L Davis; M E Brunson; K P Qian; H J Lin; S Quan; R DiNello; A J Polito; J C Scornik
Journal:  Hepatology       Date:  1993-11       Impact factor: 17.425

8.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.

Authors:  L Stuyver; R Rossau; A Wyseur; M Duhamel; B Vanderborght; H Van Heuverswyn; G Maertens
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

9.  Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay.

Authors:  K K Young; R M Resnick; T W Myers
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

10.  Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA.

Authors:  F S Nolte; C Thurmond; M W Fried
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

View more
  12 in total

Review 1.  Laboratory assays for diagnosis and management of hepatitis C virus infection.

Authors:  Sandra S Richter
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling.

Authors:  Addisalem T Makuria; Sukanya Raghuraman; Peter D Burbelo; Cathy C Cantilena; Robert D Allison; Joan Gibble; Barbara Rehermann; Harvey J Alter
Journal:  Transfusion       Date:  2012-02-05       Impact factor: 3.157

3.  Detection of hepatitis C virus by PCR in second-generation enzyme immunoassay-seropositive blood donors by using matched pairs of fresh frozen plasma and pilot tube sera.

Authors:  M Krajden; J Zhao; C Bourke; V Scalia; P Gill; W Lau
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

4.  Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals.

Authors:  A Schnuriger; S Dominguez; M-A Valantin; R Tubiana; C Duvivier; J Ghosn; A Simon; C Katlama; V Thibault
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

5.  Efficiency of the ortho VITROS assay for detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios.

Authors:  Margret Oethinger; Donald R Mayo; JoAnne Falcone; Pankaj K Barua; Brigitte P Griffith
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

6.  Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods.

Authors:  P M Schneeberger; I Keur; W van der Vliet; K van Hoek; H Boswijk; A M van Loon; W C van Dijk; R H Kauffmann; W Quint; L J van Doorn
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

7.  Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus.

Authors:  Nahed Ismail; Geoffrey E Fish; Michael B Smith
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

8.  Antigenic heterogeneity of the hepatitis C virus NS5A protein.

Authors:  Xiao-Guang Dou; Ganesh Talekar; Joy Chang; Xing Dai; Lixia Li; Maria-Teresa Bonafonte; Brian Holloway; Howard A Fields; Yury E Khudyakov
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

Review 9.  Seronegative hepatitis C virus infection.

Authors:  Justyna Kaźmierczak; Agnieszka Pawełczyk; Kamila Caraballo Cortes; Marek Radkowski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-11-09       Impact factor: 4.291

10.  Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission.

Authors:  Muhammad Idrees; Sheikh Riazuddin
Journal:  BMC Infect Dis       Date:  2008-05-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.